Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 41.5%
Concerns1
- Low return on equity of 2.3%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 6 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ409.00 Cr | β | βΉ19.00 Cr | β | β | 1.2% | 28.6% | -50.0% |
| Mar 2024 | βΉ318.00 Cr | β | βΉ38.00 Cr | β | β | 2.3% | 78.7% | -416.7% |
| Mar 2023 | βΉ178.00 Cr | β | βΉ-12.00 | β | β | 15.0% | 29.9% | -70.7% |
| Mar 2022 | βΉ137.00 Cr | β | βΉ-41.00 | β | β | 60.3% | 30.5% | 127.8% |
| Mar 2021 | βΉ105.00 Cr | β | βΉ-18.00 | β | β | 58.3% | 87.5% | 800.0% |
| Mar 2020 | βΉ56.00 Cr | β | βΉ-2.00 | β | β | 15.5% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 336 |
| Total Expenses | 385 |
| EBIT / Operating Profit | -49 |
| OPM % | -14% |
| Other Income | 57 |
| Finance Costs | 2 |
| Depreciation & Amortisation | 10 |
| Profit Before Tax | -4 |
| Tax % | - |
| Net Profit / PAT | -4 |
| EPS (βΉ) | -1 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Entero Healthcare Solutions Limitedthis co. | βΉ5.32 K Cr | βΉ409.00 Cr | 124.00 | 3.19 | 89.20 | 28.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |